Company news
Vistagen Therapeutics, Inc. news in 2026
Vistagen Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update
November 13, 2026
Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder
November 9, 2026
Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
October 20, 2026
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
September 24, 2026
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
September 22, 2026
Vistagen to Present at Psych Congress 2026
September 10, 2026
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
August 14, 2026
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
August 6, 2026
Vistagen Appoints Douglas J. Williamson to its Board of Directors
July 31, 2026
Vantage: Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)
July 27, 2026
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
June 30, 2026
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
June 15, 2026
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
June 9, 2026
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
May 27, 2026
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
May 18, 2026
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
May 12, 2026
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
May 8, 2026
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
April 21, 2026
Vistagen to Participate in Upcoming Investor Conferences
March 3, 2026
Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference
February 25, 2026
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update
February 12, 2026
Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026
February 4, 2026
Calls in 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 49 slides · September 2026
- Technical Presentation (June 2026)
Technical · 8 slides · Jun 30, 2026
- Investor Presentation (March 2026)
Investor deck · 47 slides · Mar 16, 2026
- Investor Presentation (January 2026)
Investor deck · 45 slides · Jan 9, 2026